UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 19, 2015
PROVECTUS BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
| Delaware | 001-36457 | 90-0031917 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
7327 Oak Ridge Hwy., Knoxville, Tennessee 37931
(Address of Principal Executive Offices)
(866) 594-5999
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
(a) Provectus Biopharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders on Friday, June 19, 2015.
(b) At the annual meeting, the Company’s stockholders voted on three proposals. A brief description of and tabulation of votes for each proposal are set forth below.
Proposal 1. The Company’s stockholders elected the following directors for a term of one year. There were 70,596,501 broker non-votes with respect to the proposal.
| Nominee |
For | Withheld | ||||||
| H. Craig Dees, Ph.D. |
56,215,984 | 3,733,078 | ||||||
| Timothy C. Scott, Ph.D. |
51,718,577 | 8,230,485 | ||||||
| Jan E. Koe |
52,796,995 | 7,152,067 | ||||||
| Kelly M. McMasters, M.D., Ph.D. |
57,268,275 | 2,680,787 | ||||||
| Alfred E. Smith, IV |
57,376,314 | 2,572,748 | ||||||
Proposal 2. The Company’s stockholders approved the advisory vote on the compensation of the Company’s named executive officers. There were 70,596,501 broker non-votes with respect to the proposal.
| For |
Against |
Abstain | ||
| 40,296,537 | 11,655,544 | 7,996,981 |
Proposal 3. The Company’s stockholders ratified the selection of BDO USA, LLP as the Company’s independent auditor for 2015. There were no broker non-votes with respect to the proposal.
| For |
Against |
Abstain | ||
| 126,720,215 | 1,152,287 | 2,673,061 |
| Item 7.01. | Regulation FD Disclosure. |
On June 22, 2015, Provectus Biopharmaceuticals, Inc. issued a press release (the “Press Release”) announcing that it has retained healthcare communications company PharmaHEALTHLabs to coordinate and facilitate an Investigator Advisory Board meeting to be held during 11th Brazilian Melanoma Conference from August 13-15, 2015 in Goiania, Brazil. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Pursuant to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit |
Description | |
| 99.1 | Press Release, dated June 22, 2015 | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 22, 2015
| PROVECTUS BIOPHARMACEUTICALS, INC. | ||
| By: | /s/ Peter R. Culpepper | |
| Peter R. Culpepper | ||
| Chief Financial Officer and Chief Operating Officer | ||
3
EXHIBIT INDEX
| Exhibit |
Description | |
| 99.1 | Press Release, dated June 22, 2015 | |